Gyre Therapeutics (GYRE) Change in Acquisitions & Divestments (2012 - 2026)

Gyre Therapeutics (GYRE) has 13 years of Change in Acquisitions & Divestments data on file, last reported at $10.1 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $10.1 million, down 9.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.3 million (up 27.9% YoY), and the FY2025 annual result was $15.4 million, changed N/A from the prior year.
• Change in Acquisitions & Divestments climbed to $10.1 million in Q1 2026 per GYRE's latest filing, from $4.2 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $11.2 million in Q1 2025 and troughed at $2.5 million in Q1 2022.
• A 3-year average of $7.0 million and a median of $7.2 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2026: Change in Acquisitions & Divestments plunged 90.92% in 2022, then fell 9.98% in 2026.
• A 3-year view of Change in Acquisitions & Divestments shows it stood at $2.5 million in 2022, then jumped by 69.29% to $4.2 million in 2025, then soared by 137.63% to $10.1 million in 2026.
• Business Quant data shows GYRE's Change in Acquisitions & Divestments at $10.1 million in Q1 2026, $4.2 million in Q4 2025, and $11.2 million in Q1 2025.